TABLE 1.
Clinical characteristics of the patients.
| PD-N | PD-F | p-value | |
| Participants (n) | 21 | 21 | |
| Age (years) | 64.9 ± 8.0 | 69.6 ± 7.5 | 0.061a |
| Sex (% male) | 71.4 | 52.4 | 0.204b |
| Disease duration (years) | 5.5 ± 3.1 | 4.6 ± 2.8 | 0.230a |
| MDS-UPDRS-III (0–132) | 12.8 ± 5.6 | 15.9 ± 9.5 | 0.378a |
| MDS UPDRS-III gait subscore (% > 1 score) | 38.1 | 42.9 | 0.753b |
| MDS UPDRS-III tremor subscore (% > 1 score) | 33.3 | 47.6 | 0.217b |
| MDS UPDRS-III rigidity subscore (% > 1 score) | 71.4 | 66.6 | 0.683b |
| Height (m) | 1.70 ± 0.10 | 1.67 ± 0.08 | 0.287a |
| MoCA Score (0–30) | 27.4 ± 2.1 | 26.9 ± 2.1 | 0.646a |
| LEDD | 370 ± 209 | 345 ± 212 | 0.693a |
| L-dopa LEDD | 275 ± 181 | 305 ± 189 | 0.533a |
| DA-LEDD | 53.4 ± 62.0 | 47.1 ± 55.5 | 0.725a |
| PFS-16 Score (0–16) | 2.1 ± 2.2 | 9.3 ± 2.1 | ±0.001a |
aMann-Whitney-U test, bFisher’s exact test. BMI, body mass index; DA-LEDD, dopamine-agonist LEDD; MoCA, Montreal Cognitive Assessment; L-dopa-LEDD, Levodopa LEDD; LEDD, levodopa equivalent daily dose; PFS-16, Parkinson’s disease fatigue score. Bold values represent p < 0.05.